Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics cash
Cash and short-term investments held at the end of each period.
Inhibikase Therapeutics's cash was $159.02M at Jun 30, 2026. For fiscal 2025 it was $178.76M, up 83.3% from the year before. The highest annual figure on record is $178.76M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $178.76M | +83.3% |
| FY2024 | Dec 31, 2024 | $97.54M | +636.1% |
| FY2023 | Dec 31, 2023 | $13.25M | -42.5% |
| FY2022 | Dec 31, 2022 | $23.05M | -43.4% |
| FY2021 | Dec 31, 2021 | $40.75M | +192.0% |
| FY2020 | Dec 31, 2020 | $13.95M | +75500.1% |
| FY2019 | Dec 31, 2019 | $18.46K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $159.02M | +81.4% |
| Q1 FY2026 | Mar 31, 2026 | $170.37M | +82.8% |
| Q4 FY2025 | Dec 31, 2025 | $178.76M | +83.3% |
| Q3 FY2025 | Sep 30, 2025 | $77.32M | +2283.8% |
| Q2 FY2025 | Jun 30, 2025 | $87.67M | +1004.1% |
| Q1 FY2025 | Mar 31, 2025 | $93.18M | +855.8% |
| Q4 FY2024 | Dec 31, 2024 | $97.54M | +636.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.24M | -80.7% |
| Q2 FY2024 | Jun 30, 2024 | $7.94M | -62.1% |
| Q1 FY2024 | Mar 31, 2024 | $9.75M | -62.1% |
| Q4 FY2023 | Dec 31, 2023 | $13.25M | -42.5% |
| Q3 FY2023 | Sep 30, 2023 | $16.83M | -36.6% |
| Q2 FY2023 | Jun 30, 2023 | $20.94M | -35.0% |
| Q1 FY2023 | Mar 31, 2023 | $25.72M | -29.8% |
| Q4 FY2022 | Dec 31, 2022 | $23.05M | -43.4% |
| Q3 FY2022 | Sep 30, 2022 | $26.53M | -43.3% |
| Q2 FY2022 | Jun 30, 2022 | $32.21M | +235.2% |
| Q1 FY2022 | Mar 31, 2022 | $36.61M | +162.4% |
| Q4 FY2021 | Dec 31, 2021 | $40.75M | +251941.9% |
| Q2 FY2021 | Jun 30, 2021 | $46.84M | +601525.6% |
| Q1 FY2021 | Mar 31, 2021 | $9.61M | +73004.8% |
| Q4 FY2020 | Dec 31, 2020 | $13.95M | +75500.1% |
| Q3 FY2020 | Sep 30, 2020 | $16.17K | – |
| Q2 FY2020 | Jun 30, 2020 | $7.79K | – |
| Q1 FY2020 | Mar 31, 2020 | $13.15K | – |
| Q4 FY2019 | Dec 31, 2019 | $18.46K | – |
See a number that looks wrong?